½ÃÀ庸°í¼­
»óǰÄÚµå
1542526

¼¼°èÀÇ AAV ¼öŹ °³¹ß ¹× Á¦Á¶ ±â°ü ½ÃÀå Á¶»ç º¸°í¼­ : »ê¾÷ ºÐ¼®, ±Ô¸ð, Á¡À¯À², ¼ºÀå, µ¿Çâ, ¿¹Ãø(2024-2032³â)

Global AAV Contract Development And Manufacturing Organizations Market Research Report - Industry Analysis, Size, Share, Growth, Trends and Forecast 2024 to 2032

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: Value Market Research | ÆäÀÌÁö Á¤º¸: ¿µ¹® 171 Pages | ¹è¼Û¾È³» : 1-2ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    




¡Ø º» »óǰÀº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹® ¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹® ¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.

AAV ¼öŹ °³¹ß¡¤Á¦Á¶ ±â°ü ½ÃÀåÀÇ ¼¼°è ¼ö¿ä´Â 2023³â 6¾ï 8,398¸¸ ´Þ·¯¿¡¼­ 2032³â¿¡´Â ¾à 29¾ï 9,921¸¸ ´Þ·¯ÀÇ ½ÃÀå ±Ô¸ð¿¡ ´ÞÇÒ °ÍÀ¸·Î ÃßÁ¤µÇ¸ç, Á¶»ç ±â°£ÀÎ 2024-2032³âÀÇ CAGRÀº 17.85%ÀÔ´Ï´Ù.

AAV(¾Æµ¥³ëºÎ¼öü ¹ÙÀÌ·¯½º) CDMO´Â AAV ±â¹Ý À¯ÀüÀÚ Ä¡·áÁ¦ÀÇ °³¹ß, Á¦Á¶ ¹× ½ÃÇèÀ» Àü¹®À¸·Î ÇÏ´Â ±â¾÷À¸·Î, AAV´Â ÀÛÀº Å©±âÀÇ ºñº´¿ø¼º ¹ÙÀÌ·¯½º·Î À¯ÀüÀÚ Ä¡·á¿¡¼­ À¯ÀüÀÚ µµÀÔ º¤ÅÍ·Î ÀϹÝÀûÀ¸·Î »ç¿ëµË´Ï´Ù. AAV CDMO´Â °í°´°ú Çù·ÂÇÏ¿© ƯÁ¤ Ä¡·á ¿ëµµ¿¡ ¸Â°Ô AAV º¤Å͸¦ ¼³°èÇϰí ÃÖÀûÈ­ÇÕ´Ï´Ù. ¶ÇÇÑ ¼¼Æ÷ÁÖ °³¹ß, º¤ÅÍ »ý»ê °øÁ¤ ÃÖÀûÈ­, ÃÖÁ¾ Á¦Ç° Á¤Á¦ ¹× Ư¼º Æò°¡ µî AAV º¤ÅÍ »ý»ê °ü·Ã ¼­ºñ½ºµµ Á¦°øÇÕ´Ï´Ù. ¶ÇÇÑ AAV CDMO´Â ¿ª°¡, ¼øµµ, ¹«±Õ¼º, µ¿Àϼº Å×½ºÆ®¸¦ Æ÷ÇÔÇÏ¿© AAV º¤ÅÍÀÇ ¾ÈÀü¼º°ú À¯È¿¼ºÀ» º¸ÀåÇϱâ À§ÇØ ¾ö°ÝÇÑ Å×½ºÆ®¸¦ ¼öÇàÇÕ´Ï´Ù.

½ÃÀå ¿ªÇÐ

´õ ¸¹Àº À¯ÀüÀÚ Ä¡·á Á¦Ç°ÀÌ ÀÓ»ó ½ÂÀÎÀ» ¹ÞÀ¸¸é¼­ À¯ÀüÀÚ Ä¡·á ½ÃÀåÀº ºü¸£°Ô ¼ºÀåÇϰí ÀÖÀ¸¸ç, AAV º¤ÅÍ´Â À¯ÀüÀÚ Ä¡·á Àü´ÞÀÇ ÀϹÝÀûÀÎ ¼±ÅÃÀ̸ç, À¯ÀüÀÚ Ä¡·á¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡´Â AAV CDMO ½ÃÀåÀÇ ¼ºÀåÀ» ÁÖµµÇϰí ÀÖÀ¸¸ç, AAV º¤ÅÍ ±â¼úÀÇ ¹ßÀüÀº º¤ÅÍ »ý»ê °øÁ¤ÀÇ °³¼±, µµÀÔ È¿À², ¸é¿ª ¹ÝÀÀÀÇ °¨¼Ò¸¦ °¡Á®¿Ô½À´Ï´Ù, º¤ÅÍ »ý»ê °øÁ¤ÀÇ °³¼±, µµÀÔ È¿À²ÀÇ Çâ»ó, ¸é¿ª ¹ÝÀÀÀÇ °¨¼Ò·Î À̾îÁö°í ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ¹ßÀüÀº AAV º¤Å͸¦ À¯ÀüÀÚ Ä¡·á ¿ëµµ¿¡ ´õ¿í ¸Å·ÂÀûÀ¸·Î ¸¸µé¾î AAV CDMO ¼­ºñ½º¿¡ ´ëÇÑ ¼ö¿ä¸¦ Áõ°¡½Ã۰í ÀÖ½À´Ï´Ù. ÃÖ±Ù ¼ö³â°£ À¯ÀüÀÚ Ä¡·á ¿¬±¸¿¡ ´ëÇÑ ÀÚ±Ý Áö¿øÀÌ Å©°Ô Áõ°¡ÇßÀ¸¸ç, Á¤ºÎ ±â°ü, ¹Î°£ ÅõÀÚÀÚ, ºñ¿µ¸® ´Üü µîÀÌ À¯ÀüÀÚ Ä¡·á ½ÃÀåÀÇ ¼ºÀå¿¡ ±â¿©Çϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ÀÚ±Ý Á¶´ÞÀº »õ·Î¿î À¯ÀüÀÚ Ä¡·áÁ¦ °³¹ßÀ» ÃËÁøÇÏ¿© AAV CDMO ¼­ºñ½º¿¡ ´ëÇÑ ¼ö¿ä¸¦ Áõ°¡½Ã۰í ÀÖÀ¸¸ç, FDA¿Í °°Àº ±ÔÁ¦±â°üÀº À¯ÀüÀÚ Ä¡·áÁ¦ °³¹ßÀ» ÁöÁöÇϰí À¯ÀüÀÚ Ä¡·áÁ¦ Á¦Ç°¿¡ ´ëÇÑ ½Å¼ÓÇÑ ½ÂÀÎ °æ·Î¸¦ µµÀÔÇϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ±ÔÁ¦ ´ç±¹ÀÇ Áö¿øÀº AAV CDMO ½ÃÀåÀ» Æ÷ÇÔÇÑ À¯ÀüÀÚ Ä¡·áÁ¦ ½ÃÀåÀÇ ¼ºÀåÀ» °¡¼ÓÇϰí ÀÖ½À´Ï´Ù. ¸¹Àº »ý¸í°øÇÐ ±â¾÷ ¹× Á¦¾à»çµéÀº °í°¡ÀÇ ÀÚü ½Ã¼³¿¡ ÅõÀÚÇÏ´Â ´ë½Å Àü¹® CDMO¿¡ À¯ÀüÀÚ Ä¡·áÁ¦ »ý»êÀ» À§Å¹ÇÏ´Â °ÍÀ» ¼±ÅÃÇϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ Ãß¼¼·Î ÀÎÇØ À¯ÀüÀÚ Ä¡·áÁ¦ °³¹ß ¹× Á¦Á¶¸¦ Áö¿øÇÒ °æÇèÀÌ Ç³ºÎÇÑ ÆÄÆ®³Ê¸¦ ã´Â ±â¾÷ÀÌ ´Ã¾î³ª¸é¼­ AAV CDMO ¼­ºñ½º¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡Çϰí ÀÖ½À´Ï´Ù.

Á¶»ç º¸°í¼­´Â Porter's Five Forces ¸ðµ¨, ½ÃÀå ¸Å·Âµµ ºÐ¼®, ¹ë·ùüÀÎ ºÐ¼®À» ´Ù·ç°í ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ÅøÀº »ê¾÷ ±¸Á¶¸¦ ¸íÈ®ÇÏ°Ô ÆÄ¾ÇÇÏ°í ¼¼°è ¼öÁØ¿¡¼­ °æÀïÀÇ ¸Å·ÂÀ» Æò°¡ÇÏ´Â µ¥ µµ¿òÀÌ µË´Ï´Ù. ¶ÇÇÑ ÀÌ·¯ÇÑ ÅøÀº AAV ¼öŹ °³¹ß ¹× Á¦Á¶ Á¶Á÷ ¼¼°è ½ÃÀå¿¡¼­ °¢ ºÎ¹®À» Á¾ÇÕÀûÀ¸·Î Æò°¡ÇÒ ¼ö ÀÖÀ¸¸ç, AAV ¼öŹ °³¹ß¡¤Á¦Á¶ ±â°ü »ê¾÷ÀÇ ¼ºÀå°ú Ãß¼¼´Â ÀÌ ¿¬±¸¿¡ ´ëÇÑ ÀüüÀûÀÎ Á¢±Ù ¹æ½ÄÀ» Á¦°øÇÕ´Ï´Ù.

½ÃÀå ¼¼ºÐÈ­

AAV ¼öŹ °³¹ß¡¤Á¦Á¶ ±â°ü ½ÃÀå º¸°í¼­ÀÇ ÀÌ ¼½¼Ç¿¡¼­´Â ±¹°¡ ¹× Áö¿ª ¼öÁØÀÇ ºÎ¹®¿¡ ´ëÇÑ ÀÚ¼¼ÇÑ µ¥ÀÌÅ͸¦ Á¦°øÇÏ¿© Àü·«°¡µéÀÌ °¢ Á¦Ç° ¶Ç´Â ¼­ºñ½ºÀÇ Å¸±êÃþÀ» ½Äº°Çϰí ÇâÈÄ ±âȸ¸¦ ÆÄ¾ÇÇÏ´Â µ¥ µµ¿òÀ» ÁÙ °ÍÀÔ´Ï´Ù.

¿öÅ©Ç÷ο캰

  • ¾÷½ºÆ®¸² ó¸®(º¤ÅÍ ÁõÆø ¹× µµÀÔ, º¤ÅÍ È¸¼ö ¹× äÃë)
  • ÇÏ·ù ó¸®(Á¤Á¦, ÃæÀü ¸¶¹«¸®)

¹è¾ç À¯Çüº°

  • ºÎÂø ¹è¾ç
  • ÇöŹ ¹è¾ç

¿ëµµº°

  • ¼¼Æ÷-À¯ÀüÀÚÄ¡·áÁ¦ °³¹ß
  • ¹é½Å °³¹ß
  • ¹ÙÀÌ¿ÀÀǾàǰ ¹× ½Å¾à°³¹ß
  • ¹ÙÀÌ¿À¸ÞµðÄà Á¶»ç

ÃÖÁ¾»ç¿ëÀÚº°

  • Á¦¾à ¹× ¹ÙÀÌ¿À Á¦¾à ±â¾÷
  • ÇÐ°è ¹× ¿¬±¸±â°ü

Áö¿ª ºÐ¼®

ÀÌ ¼½¼Ç¿¡¼­´Â ºÏ¹Ì, À¯·´, ¾Æ½Ã¾ÆÅÂÆò¾ç, ¶óƾ¾Æ¸Þ¸®Ä«, Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«ÀÇ AAV ¼öŹ °³¹ß¡¤Á¦Á¶ ±â°ü ½ÃÀåÀÇ ÇöÀç ¹× ¹Ì·¡ ¼ö¿ä¸¦ °­Á¶ÇÏ´Â Áö¿ª Àü¸ÁÀ» ´Ù·ì´Ï´Ù. ¶ÇÇÑ ÀÌ º¸°í¼­´Â ¸ðµç ÁÖ¿ä Áö¿ªÀÇ °³º° ¿ëµµ¿¡ ´ëÇÑ ¼ö¿ä, ÃßÁ¤ ¹× ¿¹Ãø¿¡ ÃÊÁ¡À» ¸ÂÃß¾ú½À´Ï´Ù.

Ä¿½ºÅÒ ¿ä°ÇÀÌ ÀÖ´Â °æ¿ì, ¹®ÀÇÇØÁֽñ⠹ٶø´Ï´Ù. ´ç»çÀÇ Á¶»çÆÀÀº °í°´ÀÇ ¿ä±¸¿¡ µû¶ó ¸ÂÃãÇü º¸°í¼­¸¦ Á¦°øÇÒ ¼ö ÀÖ½À´Ï´Ù.

¸ñÂ÷

Á¦1Àå ¼­¹®

Á¦2Àå °³¿ä

  • ½ÃÀåÀÇ ÇÏÀ̶óÀÌÆ®
  • ¼¼°è ½ÃÀå ½º³À¼ô

Á¦3Àå AAV ¼ö¿ë °³¹ß¡¤Á¦Á¶ ±â°ü - »ê¾÷ ºÐ¼®

  • ¼­·Ð : ½ÃÀå ¿ªÇÐ
  • ½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ
  • ½ÃÀå ¼ºÀå ¾ïÁ¦¿äÀÎ
  • ½ÃÀå ±âȸ
  • ¾÷°è µ¿Çâ
  • Porter's Five Forces ºÐ¼®
  • ½ÃÀåÀÇ ¸Å·Â ºÐ¼®

Á¦4Àå ¹ë·ùüÀÎ ºÐ¼®

  • ¹ë·ùüÀÎ ºÐ¼®
  • ¿øÀç·á ºÐ¼®
    • ¿øÀç·á ¸®½ºÆ®
    • ¿øÀç·á Á¦Á¶¾÷ü ¸®½ºÆ®
    • ÁÖ¿ä ¿øÀç·áÀÇ °¡°Ý µ¿Çâ
  • ÀáÀçÀû ¹ÙÀÌ¾î ¸®½ºÆ®
  • ¸¶ÄÉÆÃ Ã¤³Î
    • ´ÙÀÌ·ºÆ® ¸¶ÄÉÆÃ
    • ÀδÙÀÌ·ºÆ® ¸¶ÄÉÆÃ
    • ¸¶ÄÉÆÃ Ã¤³Î ¹ßÀü µ¿Çâ

Á¦5Àå ¼¼°èÀÇ AAV ¼öŹ °³¹ß¡¤Á¦Á¶ ±â°ü ½ÃÀå ºÐ¼® : ¿öÅ©Ç÷ο캰

  • ¿öÅ©Ç÷ο캰 °³¿ä
  • ½ÇÀû µ¥ÀÌÅÍ¿Í ¿¹Ãø µ¥ÀÌÅÍ
  • ¿öÅ©Ç÷ο캰 ºÐ¼®
  • ¾÷½ºÆ®¸² °øÁ¤(º¤ÅÍ ÁõÆø¡¤µµÀÔ, º¤ÅÍ È¸¼ö¡¤Ã¤Ãë)
  • ´Ù¿î½ºÆ®¸² ó¸®(Á¤Á¦, Fill Finish)

Á¦6Àå ¼¼°èÀÇ AAV ¼öŹ °³¹ß¡¤Á¦Á¶ ±â°ü ½ÃÀå ºÐ¼® : ¹è¾ç À¯Çüº°

  • ¹è¾ç À¯Çüº° °³¿ä
  • ½ÇÀû µ¥ÀÌÅÍ¿Í ¿¹Ãø µ¥ÀÌÅÍ
  • ¹è¾ç À¯Çüº° ºÐ¼®
  • ºÎÂø ¹è¾ç
  • Çöʹè¾ç

Á¦7Àå ¼¼°èÀÇ AAV ¼öŹ °³¹ß¡¤Á¦Á¶ ±â°ü ½ÃÀå ºÐ¼® : ¿ëµµº°

  • °³¿ä : ¿ëµµº°
  • ½ÇÀû µ¥ÀÌÅÍ¿Í ¿¹Ãø µ¥ÀÌÅÍ
  • ºÐ¼® : ¿ëµµº°
  • ¼¼Æ÷¡¤À¯ÀüÀÚ Ä¡·á °³¹ß
  • ¹é½Å °³¹ß
  • ¹ÙÀÌ¿ÀÀǾàǰ¡¤Pharmaceutical Discovery
  • ¹ÙÀÌ¿À¸ÞµðÄà ¿¬±¸

Á¦8Àå ¼¼°èÀÇ ÀǾàǰ °³¹ß¡¤Á¦Á¶ ¼öŹ ±â°ü ½ÃÀå ºÐ¼® : ÃÖÁ¾»ç¿ëÀÚº°

  • ÃÖÁ¾»ç¿ëÀÚº° °³¿ä
  • ½ÇÀû µ¥ÀÌÅÍ¿Í ¿¹Ãø µ¥ÀÌÅÍ
  • ÃÖÁ¾»ç¿ëÀÚº° ºÐ¼®
  • Á¦¾à¡¤¹ÙÀÌ¿ÀÀǾàǰ ±â¾÷
  • Çмú¡¤¿¬±¸±â°ü

Á¦9Àå ¼¼°èÀÇ ÀǾàǰ °³¹ß¡¤Á¦Á¶ ¼öŹ ±â°ü ½ÃÀå ºÐ¼® : Áö¿ªº°

  • Áö¿ªº° Àü¸Á
  • ¼­·Ð
  • ºÏ¹Ì ÆÇ¸Å ºÐ¼®
    • °³¿ä, ½ÇÀû°ú ¿¹Ãø
    • ºÏ¹Ì : ºÎ¹®º°
    • ºÏ¹Ì ±¹°¡º°
    • ¹Ì±¹
    • ij³ª´Ù
    • ¸ß½ÃÄÚ
  • À¯·´ ÆÇ¸Å ºÐ¼®
    • °³¿ä, ½ÇÀû°ú ¿¹Ãø
    • À¯·´ ºÎ¹®º°
    • À¯·´ ±¹°¡º°
    • ¿µ±¹
    • ÇÁ¶û½º
    • µ¶ÀÏ
    • ÀÌÅ»¸®¾Æ
    • ·¯½Ã¾Æ
    • ±âŸ À¯·´
  • ¾Æ½Ã¾ÆÅÂÆò¾ç ÆÇ¸Å ºÐ¼®
    • °³¿ä, ½ÇÀû°ú ¿¹Ãø
    • ¾Æ½Ã¾ÆÅÂÆò¾ç ºÎ¹®º°
    • ¾Æ½Ã¾ÆÅÂÆò¾ç ±¹°¡º°
    • Áß±¹
    • Àεµ
    • ÀϺ»
    • Çѱ¹
    • È£ÁÖ
    • µ¿³²¾Æ½Ã¾Æ
    • ±âŸ ¾Æ½Ã¾ÆÅÂÆò¾ç
  • ¶óƾ¾Æ¸Þ¸®Ä« ÆÇ¸Å ºÐ¼®
    • °³¿ä, ½ÇÀû°ú ¿¹Ãø
    • ¶óƾ¾Æ¸Þ¸®Ä« ºÎ¹®º°
    • ¶óƾ¾Æ¸Þ¸®Ä« ±¹°¡º°
    • ºê¶óÁú
    • ¾Æ¸£ÇîÆ¼³ª
    • Æä·ç
    • Ä¥·¹
    • ±âŸ ¶óƾ¾Æ¸Þ¸®Ä«
  • Áßµ¿ ¹× ¾ÆÇÁ¸®Ä« ÆÇ¸Å ºÐ¼®
    • °³¿ä, ½ÇÀû°ú ¿¹Ãø
    • Áßµ¿ ¹× ¾ÆÇÁ¸®Ä« ºÎ¹®º°
    • Áßµ¿ ¹× ¾ÆÇÁ¸®Ä« ±¹°¡º° ¸®½ºÆ®
    • »ç¿ìµð¾Æ¶óºñ¾Æ
    • ¾Æ¶ø¿¡¹Ì¸®Æ®
    • À̽º¶ó¿¤
    • ³²¾ÆÇÁ¸®Ä«°øÈ­±¹
    • ±âŸ Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«

Á¦10Àå AAV ¼öŹ °³¹ß¡¤Á¦Á¶ ±â°ü ±â¾÷ÀÇ °æÀï ±¸µµ

  • AAV ¼öŹ °³¹ß¡¤Á¦Á¶ ±â°ü ½ÃÀå °æÀï
  • Á¦ÈÞ¡¤Çù·Â¡¤ÇÕÀÇ
  • ÇÕº´¡¤Àμö
  • ½ÅÁ¦Ç° Ãâ½Ã
  • ±âŸ °³¹ß

Á¦11Àå ±â¾÷ °³¿ä

  • »óÀ§ ±â¾÷ÀÇ ½ÃÀå Á¡À¯À² ºÐ¼®
  • ½ÃÀå ÁýÁßµµ
  • Thermo Fischer Scientific Inc.
  • Creative Biogene
  • Catalent Inc.
  • Charles River Laboratories International Inc.
  • Danaher(Aldevron)
  • Forge Biologics
  • Genezen
  • ViroCell Biologics
  • Merck KGaA
  • Viralgen
  • Biovian Oy
  • Esco Lifesciences(Esco Aster Pte. Ltd.)
  • GenScript ProBio
  • Porton Advanced Solution Ltd
  • Ask Bio
  • Showa Denko
  • Takara Bio Inc
KSA 24.09.19

The global demand for AAV Contract Development And Manufacturing Organizations Market is presumed to reach the market size of nearly USD 2999.21 Million by 2032 from USD 683.98 Million in 2023 with a CAGR of 17.85% under the study period 2024 - 2032.

AAV (adeno-associated virus) Contract Development and Manufacturing Organizations (CDMOs) are companies that specialize in the development, manufacturing, and testing of AAV-based gene therapies. AAV is a small, non-pathogenic virus that is commonly used as a vector for gene delivery in gene therapy. AAV CDMOs work with clients to design and optimize AAV vectors for specific therapeutic applications. They also provide services for the production of AAV vectors, including the development of cell lines, optimization of vector production processes, and purification and characterization of the final product. In addition, AAV CDMOs conduct rigorous testing of the AAV vectors to ensure safety and efficacy, including tests for potency, purity, sterility, and identity.

MARKET DYNAMICS

The market for gene therapies is expanding rapidly as more gene therapy products are approved for clinical use. AAV vectors are a popular choice for gene therapy delivery, and the increasing demand for gene therapies is driving growth in the AAV CDMO market. Advances in AAV vector technology have led to improved vector production processes, increased transduction efficiency, and reduced immune responses. These advances have made AAV vectors more attractive for gene therapy applications and have increased the demand for AAV CDMO services. The availability of funding for gene therapy research has increased significantly in recent years, with government agencies, private investors, and non-profit organizations all contributing to the gene therapy market growth. This funding is driving the development of new gene therapies, which in turn is increasing demand for AAV CDMO services. Regulatory agencies such as the FDA have shown support for the development of gene therapies and have implemented expedited approval pathways for gene therapy products. This regulatory support is helping to drive growth in the gene therapy market, including the AAV CDMO market. Many biotech and pharma companies are choosing to outsource their gene therapy manufacturing to specialized CDMOs rather than investing in expensive in-house facilities. This trend is increasing demand for AAV CDMO services as these companies seek out experienced partners to help them develop and manufacture their gene therapy products.

The research report covers Porter's Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of AAV Contract Development And Manufacturing Organizations. The growth and trends of AAV Contract Development And Manufacturing Organizations industry provide a holistic approach to this study.

MARKET SEGMENTATION

This section of the AAV Contract Development And Manufacturing Organizations market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.

By Workflow

  • Upstream Processing (Vector Amplification & Expansion, Vector Recovery & Harvesting)
  • Downstream Processing (Purification, Fill Finish)

By Culture Type

  • Adherent Culture
  • Suspension Culture

By Application

  • Cell & Gene Therapy Development
  • Vaccine Development
  • Biopharmaceutical & Pharmaceutical Discovery
  • Biomedical Research

By End-User

  • Pharmaceutical & Biopharmaceutical Companies
  • Academic & Research Institutes

REGIONAL ANALYSIS

This section covers the regional outlook, which accentuates current and future demand for the AAV Contract Development And Manufacturing Organizations market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.

The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the AAV Contract Development And Manufacturing Organizations market include Thermo Fischer Scientific Inc., Creative Biogene, Catalent Inc., Charles River Laboratories International Inc., Danaher (Aldevron), Forge Biologics, Genezen, ViroCell Biologics, Merck KGaA, Viralgen, Biovian Oy, Esco Lifesciences (Esco Aster Pte. Ltd.), GenScript ProBio, Porton Advanced Solution Ltd, Ask Bio, Showa Denko, Takara Bio Inc. This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.

In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.

TABLE OF CONTENTS

1. PREFACE

  • 1.1. Report Description
    • 1.1.1 Objective
    • 1.1.2 Target Audience
    • 1.1.3 Unique Selling Proposition (USP) & offerings
  • 1.2. Research Scope
  • 1.3. Research Methodology
    • 1.3.1 Market Research Process
    • 1.3.2 Market Research Methodology

2. EXECUTIVE SUMMARY

  • 2.1. Highlights of Market
  • 2.2. Global Market Snapshot

3. AAV CONTRACT DEVELOPMENT AND MANUFACTURING ORGANIZATIONS - INDUSTRY ANALYSIS

  • 3.1. Introduction - Market Dynamics
  • 3.2. Market Drivers
  • 3.3. Market Restraints
  • 3.4. Opportunities
  • 3.5. Industry Trends
  • 3.6. Porter's Five Force Analysis
  • 3.7. Market Attractiveness Analysis
    • 3.7.1 Market Attractiveness Analysis By Workflow
    • 3.7.2 Market Attractiveness Analysis By Culture Type
    • 3.7.3 Market Attractiveness Analysis By Application
    • 3.7.4 Market Attractiveness Analysis By End-User
    • 3.7.5 Market Attractiveness Analysis By Region

4. VALUE CHAIN ANALYSIS

  • 4.1. Value Chain Analysis
  • 4.2. Raw Material Analysis
    • 4.2.1 List of Raw Materials
    • 4.2.2 Raw Material Manufactures List
    • 4.2.3 Price Trend of Key Raw Materials
  • 4.3. List of Potential Buyers
  • 4.4. Marketing Channel
    • 4.4.1 Direct Marketing
    • 4.4.2 Indirect Marketing
    • 4.4.3 Marketing Channel Development Trend

5. GLOBAL AAV CONTRACT DEVELOPMENT AND MANUFACTURING ORGANIZATIONS MARKET ANALYSIS BY WORKFLOW

  • 5.1. Overview By Workflow
  • 5.2. Historical and Forecast Data
  • 5.3. Analysis By Workflow
  • 5.4. Upstream Processing (Vector Amplification & Expansion, Vector Recovery & Harvesting) Historic and Forecast Sales By Regions
  • 5.5. Downstream Processing (Purification, Fill Finish) Historic and Forecast Sales By Regions

6. GLOBAL AAV CONTRACT DEVELOPMENT AND MANUFACTURING ORGANIZATIONS MARKET ANALYSIS BY CULTURE TYPE

  • 6.1. Overview By Culture Type
  • 6.2. Historical and Forecast Data
  • 6.3. Analysis By Culture Type
  • 6.4. Adherent Culture Historic and Forecast Sales By Regions
  • 6.5. Suspension Culture Historic and Forecast Sales By Regions

7. GLOBAL AAV CONTRACT DEVELOPMENT AND MANUFACTURING ORGANIZATIONS MARKET ANALYSIS BY APPLICATION

  • 7.1. Overview By Application
  • 7.2. Historical and Forecast Data
  • 7.3. Analysis By Application
  • 7.4. Cell & Gene Therapy Development Historic and Forecast Sales By Regions
  • 7.5. Vaccine Development Historic and Forecast Sales By Regions
  • 7.6. Biopharmaceutical & Pharmaceutical Discovery Historic and Forecast Sales By Regions
  • 7.7. Biomedical Research Historic and Forecast Sales By Regions

8. GLOBAL AAV CONTRACT DEVELOPMENT AND MANUFACTURING ORGANIZATIONS MARKET ANALYSIS BY END-USER

  • 8.1. Overview By End-User
  • 8.2. Historical and Forecast Data
  • 8.3. Analysis By End-User
  • 8.4. Pharmaceutical & Biopharmaceutical Companies Historic and Forecast Sales By Regions
  • 8.5. Academic & Research Institutes Historic and Forecast Sales By Regions

9. GLOBAL AAV CONTRACT DEVELOPMENT AND MANUFACTURING ORGANIZATIONS MARKET ANALYSIS BY GEOGRAPHY

  • 9.1. Regional Outlook
  • 9.2. Introduction
  • 9.3. North America Sales Analysis
    • 9.3.1 Overview, Historic and Forecast Data Sales Analysis
    • 9.3.2 North America By Segment Sales Analysis
    • 9.3.3 North America By Country Sales Analysis
    • 9.3.4 United States Sales Analysis
    • 9.3.5 Canada Sales Analysis
    • 9.3.6 Mexico Sales Analysis
  • 9.4. Europe Sales Analysis
    • 9.4.1 Overview, Historic and Forecast Data Sales Analysis
    • 9.4.2 Europe By Segment Sales Analysis
    • 9.4.3 Europe By Country Sales Analysis
    • 9.4.4 United Kingdom Sales Analysis
    • 9.4.5 France Sales Analysis
    • 9.4.6 Germany Sales Analysis
    • 9.4.7 Italy Sales Analysis
    • 9.4.8 Russia Sales Analysis
    • 9.4.9 Rest Of Europe Sales Analysis
  • 9.5. Asia Pacific Sales Analysis
    • 9.5.1 Overview, Historic and Forecast Data Sales Analysis
    • 9.5.2 Asia Pacific By Segment Sales Analysis
    • 9.5.3 Asia Pacific By Country Sales Analysis
    • 9.5.4 China Sales Analysis
    • 9.5.5 India Sales Analysis
    • 9.5.6 Japan Sales Analysis
    • 9.5.7 South Korea Sales Analysis
    • 9.5.8 Australia Sales Analysis
    • 9.5.9 South East Asia Sales Analysis
    • 9.5.10 Rest Of Asia Pacific Sales Analysis
  • 9.6. Latin America Sales Analysis
    • 9.6.1 Overview, Historic and Forecast Data Sales Analysis
    • 9.6.2 Latin America By Segment Sales Analysis
    • 9.6.3 Latin America By Country Sales Analysis
    • 9.6.4 Brazil Sales Analysis
    • 9.6.5 Argentina Sales Analysis
    • 9.6.6 Peru Sales Analysis
    • 9.6.7 Chile Sales Analysis
    • 9.6.8 Rest of Latin America Sales Analysis
  • 9.7. Middle East & Africa Sales Analysis
    • 9.7.1 Overview, Historic and Forecast Data Sales Analysis
    • 9.7.2 Middle East & Africa By Segment Sales Analysis
    • 9.7.3 Middle East & Africa By Country Sales Analysis
    • 9.7.4 Saudi Arabia Sales Analysis
    • 9.7.5 UAE Sales Analysis
    • 9.7.6 Israel Sales Analysis
    • 9.7.7 South Africa Sales Analysis
    • 9.7.8 Rest Of Middle East And Africa Sales Analysis

10. COMPETITIVE LANDSCAPE OF THE AAV CONTRACT DEVELOPMENT AND MANUFACTURING ORGANIZATIONS COMPANIES

  • 10.1. AAV Contract Development And Manufacturing Organizations Market Competition
  • 10.2. Partnership/Collaboration/Agreement
  • 10.3. Merger And Acquisitions
  • 10.4. New Product Launch
  • 10.5. Other Developments

11. COMPANY PROFILES OF AAV CONTRACT DEVELOPMENT AND MANUFACTURING ORGANIZATIONS INDUSTRY

  • 11.1. Top Companies Market Share Analysis
  • 11.2. Market Concentration Rate
  • 11.3. Thermo Fischer Scientific Inc.
    • 11.3.1 Company Overview
    • 11.3.2 Company Revenue
    • 11.3.3 Products
    • 11.3.4 Recent Developments
  • 11.4. Creative Biogene
    • 11.4.1 Company Overview
    • 11.4.2 Company Revenue
    • 11.4.3 Products
    • 11.4.4 Recent Developments
  • 11.5. Catalent Inc.
    • 11.5.1 Company Overview
    • 11.5.2 Company Revenue
    • 11.5.3 Products
    • 11.5.4 Recent Developments
  • 11.6. Charles River Laboratories International Inc.
    • 11.6.1 Company Overview
    • 11.6.2 Company Revenue
    • 11.6.3 Products
    • 11.6.4 Recent Developments
  • 11.7. Danaher (Aldevron)
    • 11.7.1 Company Overview
    • 11.7.2 Company Revenue
    • 11.7.3 Products
    • 11.7.4 Recent Developments
  • 11.8. Forge Biologics
    • 11.8.1 Company Overview
    • 11.8.2 Company Revenue
    • 11.8.3 Products
    • 11.8.4 Recent Developments
  • 11.9. Genezen
    • 11.9.1 Company Overview
    • 11.9.2 Company Revenue
    • 11.9.3 Products
    • 11.9.4 Recent Developments
  • 11.10. ViroCell Biologics
    • 11.10.1 Company Overview
    • 11.10.2 Company Revenue
    • 11.10.3 Products
    • 11.10.4 Recent Developments
  • 11.11. Merck KGaA
    • 11.11.1 Company Overview
    • 11.11.2 Company Revenue
    • 11.11.3 Products
    • 11.11.4 Recent Developments
  • 11.12. Viralgen
    • 11.12.1 Company Overview
    • 11.12.2 Company Revenue
    • 11.12.3 Products
    • 11.12.4 Recent Developments
  • 11.13. Biovian Oy
    • 11.13.1 Company Overview
    • 11.13.2 Company Revenue
    • 11.13.3 Products
    • 11.13.4 Recent Developments
  • 11.14. Esco Lifesciences (Esco Aster Pte. Ltd.)
    • 11.14.1 Company Overview
    • 11.14.2 Company Revenue
    • 11.14.3 Products
    • 11.14.4 Recent Developments
  • 11.15. GenScript ProBio
    • 11.15.1 Company Overview
    • 11.15.2 Company Revenue
    • 11.15.3 Products
    • 11.15.4 Recent Developments
  • 11.16. Porton Advanced Solution Ltd
    • 11.16.1 Company Overview
    • 11.16.2 Company Revenue
    • 11.16.3 Products
    • 11.16.4 Recent Developments
  • 11.17. Ask Bio
    • 11.17.1 Company Overview
    • 11.17.2 Company Revenue
    • 11.17.3 Products
    • 11.17.4 Recent Developments
  • 11.18. Showa Denko
    • 11.18.1 Company Overview
    • 11.18.2 Company Revenue
    • 11.18.3 Products
    • 11.18.4 Recent Developments
  • 11.19. Takara Bio Inc
    • 11.19.1 Company Overview
    • 11.19.2 Company Revenue
    • 11.19.3 Products
    • 11.19.4 Recent Developments

Note - In company profiling, financial details and recent developments are subject to availability or might not be covered in the case of private companies

ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
»óǰ ºñ±³Çϱâ
Àüü»èÁ¦